60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
February 20, 2024 07:59 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals will Sponsor Pre-Clinical Studies ofTafenoquine Use in Candida spp, Including Candida auris
60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
August 30, 2023 07:32 ET | Sixty Degrees Pharmaceuticals
Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp.Effective treatment of drug-resistant Candida infections is an unmet need in U.S. marketPresumed mode...
Candida + auris
Hardy Diagnostics Releases HardyCHROM™ Candida + auris
October 20, 2021 06:00 ET | Hardy Diagnostics
SANTA MARIA, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Hardy Diagnostics is pleased to announce its release of HardyCHROM™ Candida + auris, a chromogenic media recommended for the selective...
Ondine Biomedical Inc. to Present Candida auris Program Results at the 5th International Conference on Prevention & Infection Control (ICPIC, 2019, Geneva)
September 06, 2019 11:37 ET | Ondine Biomedical Inc.
Vancouver, Canada, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Ondine Biomedical Inc. announces presentation of data demonstrating high levels of efficacy of its Photodisinfection program against Candida...
PositiveID to Exhibi
PositiveID to Exhibit its Caregiver Non-Contact Thermometer at the American Association of Critical-Care Nurses Exposition May 22-24
May 21, 2018 08:00 ET | PositiveID Corporation
DELRAY BEACH, Fla., May 21, 2018 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that...